UnitedHealth Group is rated 'Buy' following the CMS's finalized 2.48% Medicare Advantage rate increase for 2027, which adds over $13 billion to the system and reduces margin risks. The company’s aggressive cost-cutting, AI investments, and strategic focus are expected to drive margin expansion and earnings growth above consensus by fiscal year 2027. Trading at a 24% discount to its five-year median P/E, UnitedHealth shows potential upside of over 40% in the next 12 to 18 months. This positive outlook follows a previous sell-off due to DOJ probe concerns and guidance cuts, which the analyst views as overblown.
Piper Sandler raised its price target for UnitedHealth Group to $475, suggesting a 13.3% upside from its current price of $419.23. The company, the largest U.S. health insurer, has consistently beaten earnings estimates, with its latest EPS of $7.23 ...
The SCHD ETF has returned just under 2% in the past month, outperforming the S&P 500 ETF (SPY) by nearly 1%. Year-to-date, about 30 SCHD holdings have more than doubled the returns of SPY, which has returned 9.8%. Additionally, 31 SCHD holdings are t...
Elevance Health and UnitedHealth Group, two of the largest U.S. health insurers, are set to report their second-quarter earnings this week. Investors and analysts are watching closely to see if these companies have maintained control over rising medi...
